Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Blood (2023) 142 (Supplement 1): 4838.

https://doi.org/10.1182/blood-2023-185507

Published: 2023

Journal Articles

Outcomes in Routine Clinical Practice with Methotrexate-Temozolomide-Rituximab Induction and Modified Etoposide-Cytarabine Consolidation in Newly Diagnosed Primary CNS Lymphoma

Blood (2023) 142 (Supplement 1): 987.

https://doi.org/10.1182/blood-2023-186742

Published: 2023

Journal Articles

Comparison of Various Stem Cell Mobilization Regimens for Multiple Myeloma - a 15-Year Retrospective Institutional Analysis from India

Blood (2023) 142 (Supplement 1): 2225.

https://doi.org/10.1182/blood-2023-182563

Published: 2023

Journal Articles

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

Blood (2023) 142 (Supplement 1): 6878.

https://doi.org/10.1182/blood-2023-180867

Published: 2023

Journal Articles

18-FDG PET-CT Scan Is a Good Tool to Detect Bone Marrow Involvement in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of 602 Patients

Manju Sengar, Tanuja Shet, Papagudi Ganesan Subramanian, Prashant Tembhare

Blood (2023) 142 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2023-189792

Published: 2023

Journal Articles

Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing

Blood (2022) 140 (Supplement 1): 4292–4293.

https://doi.org/10.1182/blood-2022-168598

Published: 2022

Journal Articles

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Blood (2022) 140 (Supplement 1): 1135–1136.

https://doi.org/10.1182/blood-2022-165715

Published: 2022

Journal Articles

Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Blood (2022) 140 (Supplement 1): 10332–10334.

https://doi.org/10.1182/blood-2022-166082

Published: 2022

Journal Articles

Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study

Vasu Babu Goli, MD, Hasmukh Jain, MD DM, Prashant Tembhare, MD, Dhanlaxmi Lalit Shetty, PhD, Avinash Bonda, MD DM, Lingaraj Nayak, MD DM, Nikhil Patkar, MD, Papagudi Ganesan Subramanian, MD, Manju Sengar, MD DM

Blood (2020) 136 (Supplement 1): 26.

https://doi.org/10.1182/blood-2020-140801

Published: 2020

Journal Articles

Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing

Nikhil Patkar, MD, Anam Fatima Shaikh, Chinmayee Kakirde, Rakhi Salve, Prasanna Bhanshe, Gaurav Chatterjee, MD, Sweta Rajpal, Swapnali Joshi, Shruti Chaudhary, Rohan Kodgule, Dhanlaxmi Lalit Shetty, PhD, Hasmukh Jain, MD, Bhausaheb Bagal, MD DM, Hari Menon, MD, Navin Khattry, MD DM, Manju Sengar, MD DM, Prashant Tembhare, MD, Papagudi Ganesan Subramanian, MD, Sumeet Gujral, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-143457

Published: 2020

Journal Articles

Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Blood (2019) 134 (Supplement_1): 1306.

https://doi.org/10.1182/blood-2019-127091

Published: 2019

Journal Articles

Genomic Landscape of Juvenile Myelomonocytic Leukemia: A Real World Context

Gaurav Chatterjee, MD, Gaurav Narula, MD, Shrinidhi Nathany, MD, Prashant Tembhare, MD, Papagudi Ganesan Subramanian, MD, Sumeet Gujral, MD, Maya Prasad, Nirmalya Roy Moulik, MD, Vasudev Bhat, Chetan A. Dhamne, MD, Shripad Banavali, MD, Nikhil Patkar, MD

Blood (2019) 134 (Supplement_1): 1728.

https://doi.org/10.1182/blood-2019-129750

Published: 2019

Journal Articles

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

Prashant Tembhare, MD, Gaurav Narula, MD, Gaurav Chatterjee, MD, Twinkle Khanka, Mahima Sanyal, Sitaram Ghogale, Nikhil Patkar, MD, Nilesh Deshpande, Yajamanam Badrinath, Sumeet Gujral, MD, Shripad Banavali, MD, Papagudi Ganesan Subramanian, MD

Blood (2019) 134 (Supplement_1): 2585.

https://doi.org/10.1182/blood-2019-128347

Published: 2019

Journal Articles

A Novel Machine Learning Derived Genomics-Based Scoring System Is Highly Predictive of Outcome in Core Binding Factor Acute Myeloid Leukemia

Nikhil Patkar, MD, Chinmayee Kakirde, Anam Fatima Shaikh, Shrinidhi Nathany, MD, Gaurav Chatterjee, MD, Prashant Tembhare, MD, Dhanlaxmi Lalit Shetty, PhD, Anant Gokarn, MD, Sachin Punatar, MBBS,MDDM MDcal Oncology, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Hasmukh Jain, MD DM, Navin Khattry, MD DM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM, Sumeet Gujral, MD, Papagudi Ganesan Subramanian, MD

Blood (2019) 134 (Supplement_1): 2710.

https://doi.org/10.1182/blood-2019-128500

Published: 2019

Journal Articles

Immunophenotypic Assessment of Minimal Residual Disease in Younger Acute Myeloid Leukemia Patients Is Highly Predictive of Outcome

Blood (2018) 132 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2018-99-116837

Published: 2018

Journal Articles

Bortezomib in Combination with Cyclophosphamide and G-CSF for Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma

Bhausaheb Bagal, MD DM, Anant Gokarn, MD DM, Avinash Bonda, MD DM, Swapnil Chavan, BSc, Sachin Punatar, MD DM, Lingaraj Nayak, MBBS, MD DM, Sadhana Kannan, MSc, Libin J Mathew, BSc, Nikhil Patkar, MD, Prashant Tembhare, MD, Minal Poojary, Shashank Ojha, Papagudi Ganesan Subramanian, MD, Sumeet Gujral, MD, Tapan Saikia, MD, Navin Khattry, MD DM

Blood (2018) 132 (Supplement 1): 2067.

https://doi.org/10.1182/blood-2018-99-116886

Published: 2018

Journal Articles

Over-Expression of ERG Predicts Poor Outcome in Acute Myeloid Leukemia

Syed Khizer Hasan, PhD, Nikhil Patkar, MD, Devanand Vishwakarma, MSc, Deepan Rajamanickam, MD, Anant Gokarn, MD, Arvind Sahu, MD, Prashant Tembhare, MD, Sadhana Kannan, MSc, Sumeet Gujral, MD, Bhausaheb Bagal, MD DM, Hasmukh Jain, MD, Hari Menon, MD, Manju Sengar, MD DM, Pratibha Kadam Amare, PhD, Papagudi Ganesan Subramanian, MD, Navin Khattry, MD DM

Blood (2017) 130 (Supplement 1): 3920.

https://doi.org/10.1182/blood.V130.Suppl_1.3920.3920

Published: 2017

Journal Articles

Presence of Minimal Residual Disease at End of Induction in Acute Myeloid Leukemia Is Predictive of Poor Outcome

Blood (2017) 130 (Supplement 1): 5109.

https://doi.org/10.1182/blood.V130.Suppl_1.5109.5109

Published: 2017

Journal Articles

Plasmacytoid Dendritic Cell Levels at End of Induction Are Predictive of MRD Clearance and Also Influence Disease Outcome in a Subset of Patients

Papagudi Ganesan Subramanian, MD, Nikhil Patkar, MD, Prashant Tembhare, MD, Yajamanam Badrinath, Sitaram Ghoghale, Sumeet Gujral, MD, Hari Menon, MD DM, Hasmukh Jain, Bhausaheb Bagal, MD DM, Manju Sengar, Navin Khattry, MD DM

Blood (2016) 128 (22): 5263.

https://doi.org/10.1182/blood.V128.22.5263.5263

Published: 2016

Journal Articles

An Integrated Genomic Classification That Includes Copy Number Alterations Is Highly Predictive of Post Induction Minimal Residual Disease (MRD) Status in Childhood Precursor B Lineage Acute Lymphoblastic Leukemia

Nikhil Patkar, MD, Papagudi Ganesan Subramanian, MD, Prashant Tembhare, MD, Pratibha Amare Kadam, PhD, Asma Bibi, MD, Karishma Chopra, MSc, Satish Mirgal, MSc, Sagar Rambhiya, MSc, Swapnali Joshi, MSc, Shruti Chaudhary, PhD, Russel Mascrenhas, MSc, Sona Dusseja, MSc, Gaurav Narula, MD, Brijesh Arora, DM, Shripad Banavali, MD, Sumeet Gujral, MD

Blood (2015) 126 (23): 2615.

https://doi.org/10.1182/blood.V126.23.2615.2615

Published: 2015

NARROW

High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial

Outcomes in Routine Clinical Practice with Methotrexate-Temozolomide-Rituximab Induction and Modified Etoposide-Cytarabine Consolidation in Newly Diagnosed Primary CNS Lymphoma

Comparison of Various Stem Cell Mobilization Regimens for Multiple Myeloma - a 15-Year Retrospective Institutional Analysis from India

E valuating the S afety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-Cel™), a Novel H umanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

18-FDG PET-CT Scan Is a Good Tool to Detect Bone Marrow Involvement in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of 602 Patients

Serum microRNA Signature Predicting Poor Therapeutic Response to Bortezomib-Based Therapy and Clinical Outcome in Newly Diagnosed Multiple Myeloma: A Result of miRNA Profiling By Deep Sequencing

Circulating Clonal Plasma Cells at Diagnosis and Peripheral Blood Measurable Residual Disease Assessment Provide Powerful Prognostication Biomarkers in Newly-Diagnosed Multiple Myeloma Patients Treated without Autologous Transplant

Phase I Trial of Humanized CD19 CART-Cell Therapy Developed in India: Safe, Active and Feasible for Outpatient Therapy

Bortezomib and Rituximab in Newly Diagnosed Adolescent and Adult CD20-Positive Philadelphia (Ph) Negative Precursor B-Cell Acute Lymphoblastic Leukemia: A Phase II Study

Molecular Measurable Residual Disease Detection in Acute Myeloid Leukemia Using Error Corrected Next Generation Sequencing

Outcomes in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL): A Report from the Indian Acute Leukemia Research Database (INwARD) of the Hematology Cancer Consortium (HCC)

Genomic Landscape of Juvenile Myelomonocytic Leukemia: A Real World Context

Flow-Cytometry Based Detection of Any Minimal Residual Disease (FC-MRD) in Children with T-Acute Lymphoblastic Leukemias (T-ALL) Is a Powerful Indicator of Outcome

A Novel Machine Learning Derived Genomics-Based Scoring System Is Highly Predictive of Outcome in Core Binding Factor Acute Myeloid Leukemia

Immunophenotypic Assessment of Minimal Residual Disease in Younger Acute Myeloid Leukemia Patients Is Highly Predictive of Outcome

Bortezomib in Combination with Cyclophosphamide and G-CSF for Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma

Over-Expression of ERG Predicts Poor Outcome in Acute Myeloid Leukemia

Presence of Minimal Residual Disease at End of Induction in Acute Myeloid Leukemia Is Predictive of Poor Outcome

Plasmacytoid Dendritic Cell Levels at End of Induction Are Predictive of MRD Clearance and Also Influence Disease Outcome in a Subset of Patients

An Integrated Genomic Classification That Includes Copy Number Alterations Is Highly Predictive of Post Induction Minimal Residual Disease (MRD) Status in Childhood Precursor B Lineage Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only